TP53 and ovarian carcinoma: Building on the aforementioned rationale, we investigated AZD5305 in a cohort of ovarian cancer patient-derived xenografts (OC-PDXs) representative of TP53-mutated high-grade serous (HGS) ovarian cancer (23, 24).